|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THYN1 |
Gene summary for THYN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THYN1 | Gene ID | 29087 |
| Gene name | thymocyte nuclear protein 1 | |
| Gene Alias | HSPC144 | |
| Cytomap | 11q25 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9P016 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29087 | THYN1 | LZE4T | Human | Esophagus | ESCC | 1.97e-03 | 2.33e-01 | 0.0811 |
| 29087 | THYN1 | LZE7T | Human | Esophagus | ESCC | 4.39e-09 | 7.43e-01 | 0.0667 |
| 29087 | THYN1 | LZE8T | Human | Esophagus | ESCC | 6.95e-03 | 1.19e-01 | 0.067 |
| 29087 | THYN1 | LZE20T | Human | Esophagus | ESCC | 4.98e-02 | 1.68e-01 | 0.0662 |
| 29087 | THYN1 | LZE24T | Human | Esophagus | ESCC | 5.45e-32 | 9.09e-01 | 0.0596 |
| 29087 | THYN1 | LZE6T | Human | Esophagus | ESCC | 2.35e-04 | 2.37e-01 | 0.0845 |
| 29087 | THYN1 | P1T-E | Human | Esophagus | ESCC | 4.05e-04 | 3.92e-01 | 0.0875 |
| 29087 | THYN1 | P2T-E | Human | Esophagus | ESCC | 2.71e-18 | 2.45e-01 | 0.1177 |
| 29087 | THYN1 | P4T-E | Human | Esophagus | ESCC | 3.50e-66 | 1.84e+00 | 0.1323 |
| 29087 | THYN1 | P5T-E | Human | Esophagus | ESCC | 1.93e-23 | 4.42e-01 | 0.1327 |
| 29087 | THYN1 | P8T-E | Human | Esophagus | ESCC | 5.30e-31 | 5.05e-01 | 0.0889 |
| 29087 | THYN1 | P9T-E | Human | Esophagus | ESCC | 1.68e-19 | 5.48e-01 | 0.1131 |
| 29087 | THYN1 | P10T-E | Human | Esophagus | ESCC | 2.08e-54 | 9.67e-01 | 0.116 |
| 29087 | THYN1 | P11T-E | Human | Esophagus | ESCC | 7.75e-14 | 6.54e-01 | 0.1426 |
| 29087 | THYN1 | P12T-E | Human | Esophagus | ESCC | 7.34e-45 | 7.14e-01 | 0.1122 |
| 29087 | THYN1 | P15T-E | Human | Esophagus | ESCC | 2.50e-14 | 3.59e-01 | 0.1149 |
| 29087 | THYN1 | P16T-E | Human | Esophagus | ESCC | 3.78e-30 | 5.99e-01 | 0.1153 |
| 29087 | THYN1 | P17T-E | Human | Esophagus | ESCC | 4.72e-08 | 3.26e-01 | 0.1278 |
| 29087 | THYN1 | P19T-E | Human | Esophagus | ESCC | 2.56e-02 | 4.69e-01 | 0.1662 |
| 29087 | THYN1 | P20T-E | Human | Esophagus | ESCC | 8.45e-27 | 5.19e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THYN1 | SNV | Missense_Mutation | c.74C>A | p.Thr25Asn | p.T25N | Q9P016 | protein_coding | tolerated(0.07) | benign(0.127) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| THYN1 | SNV | Missense_Mutation | rs202070344 | c.544C>T | p.His182Tyr | p.H182Y | Q9P016 | protein_coding | tolerated(0.29) | benign(0.029) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| THYN1 | SNV | Missense_Mutation | rs778350333 | c.370N>A | p.Ala124Thr | p.A124T | Q9P016 | protein_coding | tolerated(0.08) | probably_damaging(0.948) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| THYN1 | SNV | Missense_Mutation | c.103N>C | p.Val35Leu | p.V35L | Q9P016 | protein_coding | tolerated(0.36) | benign(0) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| THYN1 | SNV | Missense_Mutation | c.140A>T | p.Lys47Ile | p.K47I | Q9P016 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| THYN1 | SNV | Missense_Mutation | c.292G>A | p.Ala98Thr | p.A98T | Q9P016 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| THYN1 | SNV | Missense_Mutation | rs753894768 | c.507G>T | p.Met169Ile | p.M169I | Q9P016 | protein_coding | tolerated(0.12) | benign(0.04) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| THYN1 | deletion | Frame_Shift_Del | c.581delN | p.Asn194IlefsTer15 | p.N194Ifs*15 | Q9P016 | protein_coding | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |||
| THYN1 | deletion | Frame_Shift_Del | c.581delN | p.Asn194IlefsTer15 | p.N194Ifs*15 | Q9P016 | protein_coding | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| THYN1 | SNV | Missense_Mutation | novel | c.243N>C | p.Lys81Asn | p.K81N | Q9P016 | protein_coding | deleterious(0.02) | possibly_damaging(0.461) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |